FourThought Financial Partners LLC Reduces Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

FourThought Financial Partners LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 706 shares of the biopharmaceutical company’s stock after selling 12 shares during the period. FourThought Financial Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $620,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of REGN. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. MCF Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, Sutton Wealth Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.1 %

REGN traded up $19.39 during trading on Friday, hitting $957.00. 547,373 shares of the stock traded hands, compared to its average volume of 509,442. The firm has a 50-day moving average of $943.75 and a 200 day moving average of $897.24. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The firm has a market capitalization of $105.04 billion, a P/E ratio of 28.27, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 6.40 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period in the prior year, the business posted $10.96 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current year.

Analyst Upgrades and Downgrades

REGN has been the topic of several analyst reports. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $977.77.

Insiders Place Their Bets

In related news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Bonnie L. Bassler sold 854 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $979.25, for a total value of $836,279.50. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,353,323.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,095 shares of company stock worth $9,664,476. 8.83% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.